Survey Results and Recommendations from Japanese Stakeholders for Good Clinical Practice Renovation

被引:1
作者
Nakamura, Kenichi [1 ,2 ]
Ozawa, Hitoshi [1 ]
Shibata, Taro [1 ,3 ]
Ushirozawa, Nobuko [1 ,3 ]
Hata, Tomomi [1 ,2 ]
Okita, Natsuko [1 ]
Fuse, Nozomu [4 ]
Sato, Norihiro [5 ]
Ikeda, Koji [6 ]
Hanaoka, Hideki [7 ]
Maruyama, Tatsuya [8 ]
Wada, Michihiko [9 ]
Shimizu, Shinobu [10 ]
Kasai, Hiroi [11 ]
Yamamoto, Yoichi [12 ]
Sakurai, Jun [13 ]
Todaka, Koji [14 ]
Tashiro, Shimon [15 ]
Yamamoto, Haruko [16 ,17 ]
机构
[1] Natl Canc Ctr, Clin Res Support Off, Tokyo, Japan
[2] Natl Canc Ctr, Dept Int Clin Dev, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan
[3] Natl Canc Ctr, Ctr Res Adm & Support, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Clin Res Support Off, Chiba, Japan
[5] Hokkaido Univ Hosp, Clin Res & Med Innovat Ctr, Sapporo, Hokkaido, Japan
[6] Tohoku Univ Hosp, Clin Res Innovat & Educ Ctr, Sendai, Miyagi, Japan
[7] Chiba Univ Hosp, Clin Res Ctr, Chiba, Japan
[8] Univ Tokyo, Tokyo Hosp, Clin Res Support Ctr, Tokyo, Japan
[9] Keio Univ Hosp, Clin & Translat Res Ctr, Tokyo, Japan
[10] Nagoya Univ Hosp, Dept Adv Med, Nagoya, Aichi, Japan
[11] Kyoto Univ Hosp, Inst Adv Clin & Translat Sci, Kyoto, Japan
[12] Osaka Univ Hosp, Acad Clin Res Ctr, Dept Med Innovat, Osaka, Japan
[13] Okayama Univ Hosp, Ctr Innovat Clin Med, Okayama, Japan
[14] Kyushu Univ Hosp, Ctr Clin & Translat Res, Fukuoka, Japan
[15] Tohoku Univ, Grad Sch Arts & Letters, Dept Sociol, Sendai, Miyagi, Japan
[16] Natl Cerebral & Cardiovasc Ctr, Dept Data Sci, Osaka, Japan
[17] Pharmaceut & Med Devices Agcy PMDA, Tokyo, Japan
关键词
International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; Good Clinical Practice; Clinical trial regulation; Real-world data; Remote monitoring;
D O I
10.1007/s43441-021-00350-4
中图分类号
R-058 [];
学科分类号
摘要
Background The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) is undertaking a major revision of ICH E6 Good Clinical Practice (GCP) decided to involve external stakeholders in ICH-GCP renovation. Activities such as surveys and public conferences have taken place in the United States, European Union, and Japan. For stakeholder engagement in Japan, a designated research group conducted a survey of academic stakeholders. Methods A total of 105 academic stakeholders from 18 institutions responded to the survey. The research group developed recommendations reflecting the survey results and the opinions from patients and the public. Results The survey showed the top four principles needing renovation were (i) informed consent (Chapter 2.9, 12.4% of respondents believed it needed renovation), (ii) systems for quality assurance (Chapter 2.13, 9.5%), (iii) information on an investigational product (Chapter 2.4, 5.7%), and (iv) procedures on clinical trial information (Chapter 2.10, 5.7%). The top three sections identified as needing renovation were: (i) informed consent (Chapter 4.8, 27.6%), (ii) monitoring (Chapter 5.18, 22.9%), and (iii) composition, functions, and operations of the ethics committee (Chapter 3.2, 14.3%). Recommendations included clarification of ICH-GCP's scope, proportionality in various aspects of clinical trials, diversity and liquidity of ethics committee members, modernization of informed consent procedures, variations in monitoring, and regulatory grade when using real-world data. Conclusion The recommendations from Japanese investigators and patients have been submitted to the ICH E6 Expert Working Group, which will strengthen the robustness of the GCP renovation.
引用
收藏
页码:220 / 229
页数:10
相关论文
共 8 条
[1]  
[Anonymous], [No title captured]
[2]  
Clinical Trials Transformation Initiative, AACT DAT LCIM TRAILS
[3]   Stakeholders' recommendations for revising Good Clinical Practice [J].
Corneli, Amy ;
Forrest, Annemarie ;
Swezey, Teresa ;
Lin, Li ;
Tenaerts, Pamela .
CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2021, 22
[4]  
European Medicines Agency, ROT SMPC 24 03 2020
[5]   Evolution of frameworks for expediting access to new drugs in Japan [J].
Fujiwara, Yasuhiro .
NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (05) :293-294
[6]   Regulatory changes after the enforcement of the new Clinical Trials Act in Japan [J].
Nakamura, Kenichi ;
Shibata, Taro .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (04) :399-404
[7]  
Patented Medicine Prices Review Board, ANN REP 2017
[8]  
U.S Food and Drug Administration, COVID 19 FREQ ASK QU